Dimerix Appoints New Board Member
This article was originally published in Scrip
Dimerix Ltd. has appointed Liz Jazwinska to its board as non-executive director. Currently, Jazwinska is the strategic alliances director at Institute of Medical Biology, A*STAR, Singapore. She brings over 25 years of R&D management experience to the company and has previously held senior positions in industry, academia and government bodies in the UK, Singapore, Australia and New Zealand. Previously, Jazwinska founded and led Asia Pacific Partnering Group at Johnson & Johnson Research Pty Ltd. in Sydney.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.